CPT code 67516 denotes a suprachoroidal injection procedure in which medication is delivered into the suprachoroidal space between the sclera and choroid. This targeted posterior-segment delivery approach is increasingly relevant for treating retinal and choroidal conditions where localized drug distribution can improve therapeutic effect and limit systemic exposure. Nationally, adoption of suprachoroidal delivery techniques is growing as devices and agents designed for this route enter clinical use, making clear coding guidance important for consistent billing and coverage.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for 67516, typical sites of service, and the types of services the code represents. The publication also summarizes common modifiers and payer considerations where available, and highlights areas where data were not provided. This resource is intended to help revenue cycle, coding, and clinical teams understand the clinical intent of the code and what to expect when documenting and submitting claims for suprachoroidal medication injections.

Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and detailed payer-specific coverage policies.